The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
i'm very familiar with apoc3 in the scenarios you've described it and frankly i'm quite hopeful that in the near future we'll have apoc3 assays in the periphery as an increase in our armamentarium as we try to use biomarkers to better understand cardiovascular disease risk and can apoc3 levels be a part of residual risk once you've minimized apob will apoc3 tell us something above and beyond it and as you said it tracks so closely with insulin resistance and metabolic syndrome
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.